Weekly Reports | Jul 21 2023
Our top ten news from 13 July 2023 to 20 July 2023 (ranked according to popularity).
1 – ESG Focus: Waste To Energy Innovators
Tuesday 18 July 2023
Waste-to-energy is set to be a major green play over the next two decades as climate and circularity imprimaturs kick in and a swathe of new waste-to-energy technologies is coming to market. Republished to add Remondis clarification on Ipswich
2 – In Brief: Banks, Interest Rates, Construction & Corporate Bonds
Friday 14 July 2023
Weekly Broker Wrap: potential trap in being underweight Aussie banks; impacts of higher-for-longer interest rates; outlook for residential and non-residential construction & the attraction of corporate bonds.
3 – The Short Report – 13 Jul 2023
Thursday 13 July 2023
FNArena's weekly update on short positions in the Australian share market
4 – Weekly Ratings, Targets, Forecast Changes – 14-07-23
Monday 17 July 2023
Weekly update on stockbroker recommendation, target price, and earnings forecast changes
5 – Magellan Financial's June Funds Surprise
Thursday 13 July 2023
Just when investors thought it was safe to go back in the water, Magellan Financial Group reported weak June funds flows, yet brokers remain divided
6 – Bear Market Rally Or New Bull Emerging?
Friday 14 July 2023
The second half of 2023 is set up as a tug of war between still optimistic market expectations for a soft landing and more cautious economic forecasts that call for contraction. ClearBridge offers its analysis and in-house prognosis
7 – Uranium Week: Russia Under Pressure
Tuesday 18 July 2023
Russia is facing difficulties in shipping its uranium out of St Petersburg, pushing up the spot price
8 – Australian Listed Real Estate Tables – 17-07-2023
Monday 17 July 2023
FNArena provides a weekly update of Australian listed real estate trusts (REIT) and property developers, current pricing yield and valuation data
9 – GQG Partners Continues To Outperform ASX Peers
Thursday 13 July 2023
June quarter metrics for GQG Partners were well received by brokers after a strong investment performance
10 – Dr Boreham’s Crucible: Arovella Therapeutics
Monday 17 July 2023
Tim Boreham highlights the potential for cancer treatment biotech Arovella Therapeutics